These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11989927)

  • 1. Advanced breast cancer in elderly patients: which drug after tamoxifen?
    Bajetta E
    Tumori; 2002; 88(1 Suppl 1):S59-60. PubMed ID: 11989927
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
    Roseman BJ; Buzdar AU; Singletary SE
    J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aromatase inhibitors].
    Mauriac L; Bonneterre J
    Bull Cancer; 2000 Dec; 87 Spec No():5. PubMed ID: 11250603
    [No Abstract]   [Full Text] [Related]  

  • 6. Proper sequence of endocrine therapies in advanced breast cancer.
    Rose C
    Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
    Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
    Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen ("Nolvadex"): a review.
    Clemons M; Danson S; Howell A
    Cancer Treat Rev; 2002 Aug; 28(4):165-80. PubMed ID: 12363457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Perspectives of breast cancer from the ECCO-9 and from the 15th National Convention of Experimental and Clinical Oncology].
    Tumori; 1997; 83(6):979-82. PubMed ID: 9537919
    [No Abstract]   [Full Text] [Related]  

  • 10. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 11. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
    Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
    Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of letrozole versus tamoxifen as first-line therapy.
    Buzdar AU
    J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477
    [No Abstract]   [Full Text] [Related]  

  • 14. The endocrine management of postmenopausal women with early breast cancer.
    Baum M
    Breast Cancer; 2004; 11(1):15-9. PubMed ID: 14718786
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    Goss PE; Strasser K
    Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
    Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
    Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
    Lash TL; Rosenberg CL
    J Clin Oncol; 2010 Mar; 28(8):1273-5. PubMed ID: 20124162
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.